Newly diagnosed adults patients with Acute Myeloid Leukemia will be assessed as traditionally by the treating institution using classic clinical, demographic and cytogenetic variables. Complementary molecular tests will be performed in the patients included in the study using PCR to detect classic CBF (Core Binding Factor) rearrangements: CBFB-MYH11 \[inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22). NGS (Next Generation Sequencing) to detect mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT
Study Type
OBSERVATIONAL
Enrollment
100
* Detection of CBF rearrangements using PCR: CBFB-MYH11 \[inv(16)(p13;q22), isoforms A, E and D; AML-ETO (RUNX1-RUNX1T1) (t8;21)(q22;q22). * NGS panel to detect classic mutations in: FLT3-ITD and TKD, NPM1, CEBPA, RUNX1, TP53, ASXL1, IDH1, IDH2 and KIT
Hospital Regional de Alta Especialidad Ixtapaluca
Ixtapaluca, Edo Mex, Mexico
Hospital Regional de Alta Especialidad Bajío
León, Guanajuato, Mexico
Hospital Universitario
Monterrey, Nuevo León, Mexico
Imss Umae 25
Monterrey, Nuevo León, Mexico
Hospital Regional de Alta Especialidad Ciudad Victoria
Ciudad Victoria, Tamaulipas, Mexico
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico
Centro Médico Naciona Siglo XXI IMSS
Mexico City, Mexico
Hospital General de México
Mexico City, Mexico
Hospital Juarez de México
Mexico City, Mexico
Instituto Nacional de Cancerlogía
Mexico City, Mexico
overall survival
Time frame: 3 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.